'ABL301' Begins Clinical Trials, ABL Bio Receives 31.8 Billion KRW

Sanghoon Lee, CEO of ABL Bio / Photo by Chunhee Lee

[Asia Economy Reporter Chunhee Lee] ABL Bio, a bispecific antibody specialist company, announced on the 2nd that the Phase 1 clinical trial dosing of 'ABL301,' a bispecific antibody candidate for treating degenerative brain diseases such as Parkinson's disease, has begun in the United States. According to the technology licensing agreement with Sanofi, ABL Bio will receive a short-term milestone payment of $25 million (approximately 31.8 billion KRW).

This clinical trial is the first human study of ABL301, aiming to determine the initial safety and tolerability through stepwise dosing of ABL301.

ABL301 is a bispecific antibody that inhibits the accumulation of alpha-synuclein while targeting 'IGF1R' expressed at the blood-brain barrier (BBB) to enhance antibody brain delivery. In January last year, ABL Bio signed a joint development and technology transfer agreement with Sanofi worth a total of $1.06 billion (approximately 1.3472 trillion KRW) for ABL301. ABL Bio leads the Phase 1 clinical trial, and Sanofi is responsible for subsequent clinical development and commercialization.

Lee Sang-hoon, CEO of ABL Bio, said, “We are pleased to announce the start of the Phase 1 clinical trial of ABL301,” adding, “Based on close cooperation with Sanofi, we will accelerate the clinical progress of ABL301 and do our best to provide a better life for Parkinson's patients worldwide.”

This content was produced with the assistance of AI translation services.